Shengshi Taikang and Medicis Announce Strategic Collaboration on PROTAC Project

Recently, Shengshi Taikang Biotechnology Co., Ltd. and MedicWest Biopharmaceuticals Co., Ltd. successfully established a strategic partnership on a PROTAC project. Under this collaboration, Shengshi Taikang will leverage MedicWest's proven expertise in PROTAC technology— a cutting-edge approach that diverges from traditional drug development strategies focused on inhibiting the activity or function of disease-causing proteins. Instead, PROTAC therapy harnesses the body’s natural protein degradation mechanisms to eliminate pathogenic target proteins, offering a novel way to intervene in or treat diseases.

Dr. Yu Qiang and Dr. Ren Feng completed the online signing ceremony.

Medici's Chemistry Division has compiled a comprehensive library of highly potent small molecules and small-molecule fragments targeting currently popular drug discovery targets, including the TPSM library (high-affinity small molecules and fragments for key therapeutic proteins), the E3SM library (high-affinity small molecules and fragments for versatile E3 ligases), and a diverse range of bifunctional linkers known as BF-Linkers. Leveraging these resources, the team has successfully engineered a series of PROTAC-based protein-degrading chimeras, significantly advancing the drug discovery process through innovative PROTAC technology.

Medici has simultaneously established and refined a PROTAC-based bio-screening and testing platform. The Biology Department boasts mature PROTAC functional assay and validation technologies, leveraging techniques such as fusion protein expression and BiFC (Bimolecular Fluorescence Complementation) to create a high-throughput PROTAC screening platform. This platform is designed to identify PROTAC small molecules that specifically target and degrade disease-causing proteins.

After the meeting, Dr. Yu Qiang, CEO of Shengshi Taikang, also composed a "hidden-tail poem," expressing his heartfelt hopes and best wishes for the collaborative project that is about to begin:

A towering peak resembles an axe. P ，

Mountains rise, with steep cliffs standing tall.

No time for leisurely clouds R A O ,

Reach the summit, and heaven is yours. T 。

The Dream of a Prosperous Era as m A ，

Tongcheng Medi C ！

About Shengshi Taikе

Shengshi Taikang Biopharmaceutical Technology (Suzhou) Co., Ltd. is a high-tech enterprise dedicated to the research, development, production, and commercialization of innovative small-molecule drugs. Since its establishment, the company has filed multiple invention patent applications and has already been granted 2 authorized patents. Notably, its Class 1.1 antidiabetic drug, senglitinib—a patented compound—has successfully been included in China’s 12th and 13th Five-Year Plans for "Major New Drug Development," placing it on the national stage as a key focus for innovative pharmaceuticals. Preclinical studies have demonstrated that senglitinib outperforms its global counterpart, sitagliptin, significantly in both key technical parameters and long-term therapeutic benefits. In 2017, senglitinib also received clinical trial approval from China’s National Medical Products Administration. Meanwhile, Shengshi Taikang’s flash-release formulation technology has earned recognition as a Suzhou City Engineering Center, serving as a platform for developing cutting-edge new drug projects—such as aripiprazole-based specialty formulations—and paving the way for future R&D efforts focused on additional Class 2 improved new drugs.

About Medicis

Medici (stock code: 688202) was founded in 2004 and is headquartered in Shanghai. The company is dedicated to providing comprehensive preclinical drug research services to global pharmaceutical companies, research institutions, and scientists worldwide. With its one-stop integrated services, Medici leverages robust project management and highly efficient, cost-effective R&D solutions to help clients accelerate their drug development processes. Its offerings cover the entire spectrum of preclinical drug research, including drug discovery, pharmaceutical studies, and preclinical evaluations. Together with esteemed domestic and international clients, Medici has grown alongside them, serving over 700 global partners with cutting-edge drug development expertise. Moving forward, Medici will remain firmly rooted in a global perspective while doubling down on China’s innovative strengths, continuing to contribute to human health and well-being!